162162

G00002

ABSTRACT

HUMAN MONOCLONAL ANTIBODY AGAINST A COSTIMULATORY SIGNAL TRANSDUCTION MOLECULE AILIM AND PHARMACEUTICAL USE THEREOF

One aspect of the present invention relates to a pharmaceutical composition for prevention, treatment, or prophylaxis of delayed type allergy, comprising a substance having an activity in modulating signal transduction mediated by a co-stimulatory molecule, AILIM, and a pharmaceutically acceptable carrier. Another aspect of the present invention relates to a method for identifying substances that bind to the AILIM or AILIM ligand. This method allows for screening for candidate pharmaceuticals (chemical synthetic compounds or antibodies) with potential activity to treat various disorders by binding to AILIM or AILIM ligands to regulate signal transduction mediated by interaction of AILIM or AILIM ligands. The substance so identified enables suppression, prevention and/or treatment of various disorders caused by diverse physiological phenomena related to signal transduction mediated by AILIM and AILIM ligand pathway.

Figure 72